Related Experiment Video
Updated: Jan 19, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Feraheme (Ferumoxytol) Is Recognized by Proinflammatory and Anti-inflammatory Macrophages via Scavenger Receptor Type
Guankui Wang1, Natalie J Serkova1,2, Ernest V Groman1
1Colorado Center for Nanomedicine and Nanosafety , University of Colorado Anschutz Medical Campus , Aurora , Colorado 80045 , United States.
Abstract:
Feraheme (ferumoxytol), a negatively charged, carboxymethyl dextran-coated ultrasmall superparamagnetic iron oxide nanoparticle (USPIO, 30 nm, -16 mV), is clinically approved as an iron supplement and is used off-label for magnetic resonance imaging (MRI) of macrophage-rich lesions, but the mechanism of recognition is not known. We investigated mechanisms of uptake of Feraheme by various types of macrophages in vitro and in vivo. The uptake by mouse peritoneal macrophages was not inhibited in complement-deficient serum. In contrast, the uptake of larger and less charged SPIO nanoworms (60 nm, -5 mV; 120 nm, -5 mV, respectively) was completely inhibited in complement deficient serum, which could be attributed to more C3 molecules bound per nanoparticle than Feraheme. The uptake of Feraheme in vitro was blocked by scavenger receptor (SR) inhibitor polyinosinic acid (PIA) and by antibody against scavenger receptor type A I/II (SR-AI/II). Antibodies against other SRs including MARCO, CD14, SR-BI, and CD11b had no effect on Feraheme uptake. Intraperitoneally administered PIA inhibited the peritoneal macrophage uptake of Feraheme in vivo. Nonmacrophage cells transfected with SR-AI plasmid efficiently internalized Feraheme but not noncharged ultrasmall SPIO of the same size (26 nm, -6 mV), suggesting that the anionic carboxymethyl groups of Feraheme are responsible for the SR-AI recognition. The uptake by nondifferentiated bone marrow derived macrophages (BMDM) and by BMDM differentiated into M1 (proinflammatory) and M2 (anti-inflammatory) types was efficiently inhibited by PIA and anti-SR-AI/II antibody. Interestingly, all BMDM types expressed similar levels of SR-AI/II. In conclusion, Feraheme is efficiently recognized via SR-AI/II but not via complement by different macrophage types. The recognition by the common phagocytic receptor has implications for specificity of imaging of macrophage subtypes.
Insights
Feraheme (ferumoxytol) is recognized by macrophages via scavenger receptor type A I/II (SR-AI/II), not complement. This finding is crucial for understanding its use in imaging macrophage-rich lesions.
Area of Science:
- Nanomedicine
- Immunology
- Biochemistry
Background:
- Feraheme (ferumoxytol) is an iron oxide nanoparticle used for iron supplementation and off-label for MRI of macrophage-rich lesions.
- The specific mechanism by which macrophages recognize Feraheme is currently unknown.
- Understanding Feraheme's cellular uptake is vital for optimizing its diagnostic and therapeutic applications.
Purpose of the Study:
- To elucidate the cellular uptake mechanisms of Feraheme by macrophages.
- To determine the role of complement and scavenger receptors in Feraheme recognition.
- To investigate Feraheme's interaction with different macrophage subtypes.
Main Methods:
- In vitro studies using mouse peritoneal macrophages and bone marrow-derived macrophages (BMDM).
- In vivo experiments involving intraperitoneal administration of Feraheme and inhibitors.
- Utilized complement-deficient serum, scavenger receptor inhibitors (polyinosinic acid), and antibodies against specific scavenger receptors (SR-AI/II, MARCO, CD14, SR-BI, CD11b).
- Transfection of non-macrophage cells with SR-AI plasmid to assess Feraheme internalization.
Main Results:
- Feraheme uptake was not inhibited by complement-deficient serum, unlike larger SPIOs.
- Scavenger receptor type A I/II (SR-AI/II) and its inhibitor polyinosinic acid significantly blocked Feraheme uptake.
- Non-charged ultrasmall SPIOs were not internalized by SR-AI-transfected cells, indicating the importance of Feraheme's anionic carboxymethyl groups.
- All tested macrophage subtypes (undifferentiated, M1, M2) showed efficient Feraheme uptake via SR-AI/II.
Conclusions:
- Feraheme is primarily recognized by macrophages through scavenger receptor type A I/II (SR-AI/II).
- Complement pathways do not play a significant role in Feraheme uptake.
- This specific recognition mechanism by SR-AI/II has implications for targeted imaging of macrophage subtypes.
Related Concept Videos
Phagocytosis of Apoptotic Cells
Normal cells contain receptors that prevent them from being recognized...
Immune Surveillance by NK Cells and Phagocytes
Natural Killer Cells: The Fast Responders
NK cells are large granular lymphocytes found in the blood and lymphatic system. These...
The Early Endosome: Endocytosis of Transferrin

